Publications

Authors:

Gajofatto, Alberto; Turatti, Marco

Title:

Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis

Year:

2018

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

Sì

Name of journal:

Expert Opinion on Investigational Drugs

ISSN of journal:

1354-3784

N° Volume:

27

Number or Folder:

3

Page numbers:

273-286

Keyword:

B-cell therapy; clinical trial; experimental drug; immunosuppressant; monoclonal antibody; multiple sclerosis; sphingosine 1-phosphate modulator

Short description of contents:

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with an immune mediated pathogenesis. Several therapies that suppress or modulate diverse immune system functions have been used for decades with the aim of modifying the disease course. However, these treatments have either limited efficacy or potentially serious adverse events that prevent first-line use on large scale. Areas covered. The aim of the present article is to review ongoing or recently completed clinical trials investigating immunosuppressive drugs for MS. The websites clinicaltrials.gov, clinicaltrialsregister.eu, and pubmed.gov were searched for phase 1, phase 2, and phase 3 trials starting from 2012. Twelve drugs were identified, including 7 monoclonal antibodies and 5 small molecules. Expert opinion. Current or recently completed trials of immunosuppressants for MS are mainly proof-of-concept studies enrolling patients with relapsing disease and using efficacy endpoints based on magnetic resonance imaging measures of inflammatory activity. Sphingosine 1-phosphate receptor modulators and B-cell depleting therapies represent the most commonly investigated drugs, suggesting that mechanisms of action that have already shown promise for MS treatment are being exploited to find new therapies with improved safety, tolerability, and convenience of dosing. Clinical trials of immunosuppressants for progressive MS are largely lacking.

Web page:

https://doi.org/10.1080/13543784.2018.1442437

Product ID:

101649

Handle IRIS:

11562/976192

Last Modified:

November 26, 2022

Bibliographic citation:

Gajofatto, Alberto; Turatti, Marco, Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis «Expert Opinion on Investigational Drugs» , vol. 27 , n. 3 , 2018 , pp. 273-286

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo